This activity is for healthcare professionals outside of the UK.

This activity is provided by an independent medical education grant from Merck Sharp & Dohme LLC, Rahway, NJ, USA.

The activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. 

    Download Slides
    Download Practice Aid
    Download Slides
    Download Practice Aid
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Antoni Torres

    University of Barcelona, Spain

    Antoni Torres is full professor of medicine (pulmonology) at the University of Barcelona. He has been director and chief of the Pulmonology Department, and director of the Respiratory Intensive Care Unit at Hospital Clinic of Barcelona.read more

    Prof Torres obtained his degree in medicine from the University of Barcelona. He performed his residency in internal medicine and pulmonology at Hospital Clinic, Barcelona and later completed a research fellowship programme at Harvard University, Massachussetts General Hospital, Boston, MA, USA.

    He leads a translational research group focused on respiratory infections, acute respiratory distress syndrome and critical care. He has received several research awards, including the Edward Shanoff Award for research (Harvard University), Josep Trueta award, Lilly award, Barcelona College of Doctors award, Icrea Academia award, and the CHEST Murray Kornfeld Memorial (American College Of Chest Physician).

    Prof. Torres discloses Speaker’s bureau fees from Byoversis, MSD, Paratek Pharma and Pfizer.
    Back to Faculty
    touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    SEE ALL VIDEOS
    Start activity

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What is the biggest challenge you face in applying pneumococcal vaccination guidelines in practice?

    Submit your answer to see the results

    Identifying eligible individuals
       
    Vaccine availability
       
    Vaccine hesitancy by patient
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which factor mainly influences which pneumococcal vaccine you recommend to eligible patients?

    Submit your answer to see the results

    Guideline recommendations
       
    Efficacy data
       
    Safety profile
       
    Other
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    How confident do you feel in identifying individuals at risk of invasive pneumococcal disease?

    Submit your answer to see the results

    Not confident
       
    A little confident
       
    Moderately confident
       
    Very confident
       
     
    Expert Interviews
    Vaccines, Respiratory Infections, Bacterial Infections CE/CME accredited

    touchEXPERT OPINIONS
    Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity. Close

    Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact

    Take CE/CME Test

    Antoni Torres is full professor of medicine (pulmonology) at the University of Barcelona. He has been director and chief of the Pulmonology Department, and director of the Respiratory Intensive Care Unit at Hospital Clinic of Barcelona.read more

    Prof Torres obtained his degree in medicine from the University of Barcelona. He performed his residency in internal medicine and pulmonology at Hospital Clinic, Barcelona and later completed a research fellowship programme at Harvard University, Massachussetts General Hospital, Boston, MA, USA.

    He leads a translational research group focused on respiratory infections, acute respiratory distress syndrome and critical care. He has received several research awards, including the Edward Shanoff Award for research (Harvard University), Josep Trueta award, Lilly award, Barcelona College of Doctors award, Icrea Academia award, and the CHEST Murray Kornfeld Memorial (American College Of Chest Physician).

    Prof. Torres discloses Speaker’s bureau fees from Byoversis, MSD, Paratek Pharma and Pfizer.

    Take CE/CME Test

    Antoni Torres is full professor of medicine (pulmonology) at the University of Barcelona. He has been director and chief of the Pulmonology Department, and director of the Respiratory Intensive Care Unit at Hospital Clinic of Barcelona.read more

    Prof Torres obtained his degree in medicine from the University of Barcelona. He performed his residency in internal medicine and pulmonology at Hospital Clinic, Barcelona and later completed a research fellowship programme at Harvard University, Massachussetts General Hospital, Boston, MA, USA.

    He leads a translational research group focused on respiratory infections, acute respiratory distress syndrome and critical care. He has received several research awards, including the Edward Shanoff Award for research (Harvard University), Josep Trueta award, Lilly award, Barcelona College of Doctors award, Icrea Academia award, and the CHEST Murray Kornfeld Memorial (American College Of Chest Physician).

    Prof. Torres discloses Speaker’s bureau fees from Byoversis, MSD, Paratek Pharma and Pfizer

    Take CE/CME Test

    Antoni Torres is full professor of medicine (pulmonology) at the University of Barcelona. He has been director and chief of the Pulmonology Department, and director of the Respiratory Intensive Care Unit at Hospital Clinic of Barcelona.read more

    Prof Torres obtained his degree in medicine from the University of Barcelona. He performed his residency in internal medicine and pulmonology at Hospital Clinic, Barcelona and later completed a research fellowship programme at Harvard University, Massachussetts General Hospital, Boston, MA, USA.

    He leads a translational research group focused on respiratory infections, acute respiratory distress syndrome and critical care. He has received several research awards, including the Edward Shanoff Award for research (Harvard University), Josep Trueta award, Lilly award, Barcelona College of Doctors award, Icrea Academia award, and the CHEST Murray Kornfeld Memorial (American College Of Chest Physician).

    Prof. Torres discloses Speaker’s bureau fees from Byoversis, MSD, Paratek Pharma and Pfizer.

    Take CE/CME Test
    Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Outline the need for next-generation vaccines to prevent invasive pneumococcal disease in vulnerable groups
    • Evaluate the efficacy and safety data for next-generation pneumococcal vaccinations in adult and paediatric populations, including the resulting impact on public health
    • Summarize the latest guidelines for pneumococcal vaccination in adult and paediatric populations
    Overview

    In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneumococcal infections.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    Infectious disease specialists, pharmacists and primary care physicians involved in the management of patients at risk of pneumococcal disease.

    USF Accreditation

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Torres discloses Speaker’s bureau fees from Byoversis, MSD, Paratek Pharma and Pfizer.

    Content reviewer

    Danielle Walker, DNP, APRN, AGNP-C has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Contributors

    Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 5 November 2024. Date credits expire: 5 November 2025.

    If you have any questions regarding credit, please contact cpdsupport@usf.edu

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hour of effective education time.

    The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.

    Faculty Disclosure Statement/Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Date of original release: 5 November 2024. Date credits expire: 5 November 2025.

    Time to Complete: 47 minutes

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org 

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    JOURNALS

    More than Baby Steps: Preventing Respiratory Syncytial Virus in Infants

    GO TO ARTICLE

    JOURNALS

    Erythrasma: A Superficial Cutaneous Bacterial Infection Overlooked in Clinical Practice

    GO TO ARTICLE

    touchEXPERT OPINIONS

    The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023

    GO TO HUB

    touchIN CONVERSATION

    Practical considerations for COVID-19 vaccination in the Middle East

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Angus Thomson: Addressing vaccine hesitancy, global vaccine uptake, and communication methods

    GO TO HUB

    Topics covered in this activity

    Vaccines / Respiratory Infections / Bacterial Infections
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is jointly funded by:

    An independent medical education grant from Merck Sharp & Dohme LLC, Rahway, NJ, USA.
    This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBAC® 

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK.

    Date of original release: 5 November 2024. Date credits expire: 5 November 2025

    Claim Credit
    touchEXPERT OPINIONS
    Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact
    0.75 CE/CME credit
    Question 1/5
    You have an adult patient (19–64 years old) with chronic lung disease, who received only PCV13 over 1 year ago. How would you advise them about their protection against CAP?

    CAP, community acquired pneumonia; PCV, pneumococcal conjugate vaccine.

    According to the latest guidance, all individuals <5 years and ≥65 years of age should be vaccinated against pneumococcal disease. Furthermore, individuals 6–64 years of age with a relevant risk condition (including chronic lung disease) or who are immunocompromised are eligible for vaccination.1,2 PCV13 does not cover many of the emerging serotypes associated with CAP,3 and vaccination with a single dose of PCV21, PCV20 or PPSV23 is recommended for adult patients with chronic conditions who have only received PCV13 ≥1 year before.4

    Abbreviations

    CAP, community acquired pneumonia; PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine.

    References

    1. Centers for Disease Control and Prevention. Pneumococcal Vaccine Recommendations. October 2024. Available at: www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html (accessed 16 October 2024).
    2. Centers for Disease Control and Prevention. Summary of Risk-Based Pneumococcal Vaccination Recommendations. 16 October 2024. Available at: www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/risk-indications.html (accessed 16 October 2024).
    3. Lansbury L, et al. Lancet Reg Health Eur. 2023;37:100812.
    4. Kobayashi M, et al. MMWR Morb Mortal Wkly Rep. 2024;73:793–8.
    Question 2/5
    You are practising in a location where cases of CAP and IPD are on the rise. Which of the following available conjugate vaccines would provide eligible adults with protection against the majority of emerging serotypes associated with severe PD?

    CAP, community acquired pneumonia; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.

    Among the available PCVs, PCV20 and PCV21 provide protection against a broader spectrum of PD serotypes, including those identified as being associated with CAP and IPD in recent epidemiological studies.1–8 Specifically, of the 13 PD serotypes which emerged in studies for Europe, the UK and the USA as being responsible for the majority of PD and IPD cases, four are covered by PCV13, five by PCV15, and ten by PCV20 or PCV21.1–8

    Abbreviations

    CAP, community acquired pneumonia; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PD, pneumococcal disease.

    References

    1. Teixeira R, et al. Microorganisms. 2023;11:1376.
    2. Lansbury L, et al. Lancet Reg Health Eur. 2023;37:100812.
    3. Orsi A, et al. Microorganisms. 2022;11:70.
    4. Torres A, et al. Clin Infect Dis. 2021;73:1075–85.
    5. Pérez-García C, et al.J Infect. 2024;89:106204.
    6. Self WH, et al. . 2024. doi: 10.1093/cid/ciae316; 7.
    7. Kobayashi M, et al. MMWR Morb Mortal Wkly Rep. 2024;73:793–8.
    8. Scelfo C, et al. Vaccines. 2021;9:420.
    Question 3/5
    Which of the following statements summarises key trial outcomes for PCV15 (PNEU-AGE), PCV20, and PCV21 (STRIDE-3 and -6) in adults?

    PCV, pneumococcal conjugate vaccine.

    OPA GMT non-inferiority criteria were met across all four trials versus comparator vaccine-matched serotypes.1–4

    In the PCV15 PNEU-AGE trial, superiority criteria were met for PCV15-unique serotypes.1 In the PCV20 trial in adults, non-inferiority criteria were met for 6 of 7 PCV20-unique serotypes.2 In STRIDE-3, superiority criteria were met for 10 of 11 PCV21-unique serotypes, and in STRIDE-6, a higher response vs comparator was observed against PCV21-unique serotypes.3,4

    Abbreviations

    GMT, geometric mean titre; IgG, immunoglobulin G; OPA, opsonophagocytic activity; PCV, pneumococcal conjugate vaccine.

    References

    1. Platt HL, et al. Vaccine. 2022;40:162–72.
    2. Essink B, et al. Clin Infect Dis. 2022;75:390–8.
    3. Platt HL, et al. Lancet Infect Dis. 2024;24:1141–50.
    4. Scott P, et al. Clin Infect Dis. 2024. doi: 10.1093/cid/ciae383.
    Question 4/5
    You are managing a 55-year-old immunocompromised patient who has only received PPSV23 in the past. What is the most appropriate course of action for vaccinating this patient?

    PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine.

    According to the updated 2024 ACIP guidance for adults, patients who are 19–64 years age with an immunocompromising condition and who have only received prior PPSV23 should receive a single dose of PCV21, PCV20 or PCV15 ≥1 year after the PPSV23 dose.

    Abbreviations

    ACIP, Advisory Committee on Immunization Practices; PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine.

    Reference

    Kobayashi M, et al. MMWR Morb Mortal Wkly Rep. 2024;73:793–8.

    Question 5/5
    Your patient is 71 years old. Their vaccination history shows that 7 years ago they received PCV13, and PPSV23 prior to that. They want to know whether they should receive any further PD vaccines. What do you recommend?

    PCV, pneumococcal conjugate vaccine; PD, pneumococcal disease; PPSV, pneumococcal polysaccharide vaccine.

    According to the updated 2024 ACIP guidance for adults, patients who are ≥65 years of age and who have had prior PCV13 at any age + PPSV23 at age <65 years should receive a single dose of PCV21 or PCV20 ≥5 years after their last PCV dose, or PPSV23 ≥1 year later (or ≥8 weeks later if immunocompromised, with cochlear implant or CSF leak) and ≥5 years after last PPSV23 dose.

    Abbreviations

    ACIP, Advisory Committee on Immunization Practices; CSF, cerebrospinal fluid; PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine.

    Reference

    Kobayashi M, et al. MMWR Morb Mortal Wkly Rep. 2024;73:793–8.

    Back to Activity

    You may also be interested in...

    JOURNALS

    More than Baby Steps: Preventing Respiratory Syncytial Virus in Infants

    GO TO ARTICLE

    JOURNALS

    Erythrasma: A Superficial Cutaneous Bacterial Infection Overlooked in Clinical Practice

    GO TO ARTICLE

    touchEXPERT OPINIONS

    The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023

    GO TO HUB

    touchIN CONVERSATION

    Management of patients with NTM-LD: Improving adherence for optimal outcomes

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Angus Thomson: Barriers to vaccine acceptance in a post-COVID world

    GO TO HUB
    This activity is jointly funded by:

    An independent medical education grant from Merck Sharp & Dohme LLC, Rahway, NJ, USA.
    This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBAC® 

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK.

    Date of original release: 5 November 2024. Date credits expire: 5 November 2025

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup